ABBV
Companies
Nyse American
AbbVie Inc.
Health Care
$185.48
+$10.78 (+6.17%)
Price Chart
Overview
About ABBV
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Market Cap
$299.2B
Volume
1.7B
Avg. Volume
1.1B
P/E Ratio
78.89
Dividend Yield
3.55%
Employees
50.0K
Company Information
Exchange
Nyse American
Sector
Health Care
Industry
Drug Manufacturers - General
Website
Latest News for ABBV
3 Stocks That Will Profit From Trump's Drug Price Cut
May 16, 2025
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
June 17, 2025
Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie
June 13, 2025
Is It Time To Buy AbbVie Stock At $180?
May 16, 2025
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
June 17, 2025
Risk & Correlation Analysis
Market Correlation
0.59
Low Correlation
Volatility
Medium (0.30)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ABBV shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$299.2B
Volume1.7B
P/E Ratio78.89
Dividend Yield3.55%
Important Dates
Next Dividend
Next Earnings
April 25, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025